Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01275664 · ClinicalTrials.gov registry record · NA
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
A NA study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT01275664 is a NA study that was terminated before completion, run by Gynecologic Oncology Group. The registered enrollment target is 4 participants.
The verdict
NCT01275664, a NA study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Dexamethasone
- DRUG Aprepitant
- PROCEDURE Adjuvant Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01275664
The ClinicalTrials.gov registry entry for NCT01275664 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01275664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01275664 about?
NCT01275664 is a clinical study titled "Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer". This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen or prevent nausea and vom...
What is the current status of trial NCT01275664?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2011-06.
What interventions are being tested in trial NCT01275664?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Dexamethasone (DRUG), Aprepitant (DRUG), Adjuvant Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT01275664?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.